Skip to main content
. 2018 Feb 20;12:89. doi: 10.3389/fnins.2018.00089

Figure 3.

Figure 3

Reduced MMP-9 and MMP-3 Activity in ischemic rats given the EP4 Agonist L-902,688. We measured reduced MMP-9 protein with immunoblotting after 24 h of reperfusion in the (A) cortex (*P < 0.05) and (B) the subcortex (P = 0.0792). There was reduced MMP-9 activity with L-902,688 treatment in the cortex (C), but not in the subcortex (D). (E) In the cerebral cortex, 1.0 mg/kg L-902,688 significantly reduces MMP-3 activity in the ipsilateral side of the treated group vs. the vehicle group. *P = 0.0215. (F) In the subcortex, the effect of L-902,688 in the ipsilateral hemisphere is less pronounced (P = 0.1304). CXI, ipsilateral cortex; CXC, contralateral cortex; STI, ipsilateral subcortex; STC, contralateral subcortex. Vehicle (n = 10) and 1.0 mg/kg L-902,688 (n = 8).